Lukas Theo Schmitt

Lukas Theo Schmitt

Auto-generated profile, based on publicly available information

Lukas Theo Schmitt

Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
SSShady Sayed
Shady Sayed
OSOlga A. Sidorova
Olga A. Sidorova
AHAlexander Hennig
Alexander Hennig
MAMartina Augsburg
Martina Augsburg
CVCatherine P. Cortés Vesga
Catherine P. Cortés Vesga
FBFrank Buchholz
Frank Buchholz
KRAS is the most frequently mutated oncogene in human cancer, and its activating mutations represent long-sought therapeutic targets. Programmable nucleases, particularly the CRISPR-Cas9 system, provide an attractive tool for genetically targeting KRAS mutations in cancer cells. Here, we show that cleavage of a panel of KRAS driver mutations suppresses growth in various human cancer cell lines, revealing their dependence on mutant KRAS. However, analysis of the remaining cell population after long-term Cas9 expression unmasked the occurence of oncogenic KRAS escape variants that were resistant to Cas9-cleavage. In contrast, the use of an adenine base editor to correct oncogenic KRAS mutations progressively depleted the targeted cells without the appearance of escape variants and allowed efficient and simultaneous correction of a cancer-associated TP53 mutation. Oncogenic KRAS and TP53 base editing was possible in patient-derived cancer organoids, suggesting that base editor approaches to correct oncogenic mutations could be developed for functional interrogation of vulnerabilities in a personalized manner for future precision oncology applications. Significance: Repairing KRAS mutations with base editors can be used for providing a better understanding of RAS biology and may lay the foundation for improved treatments for KRAS-mutant cancers.

27 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LSLukas Theo Schmitt
Lukas Theo Schmitt
MPMaciej Paszkowski-Rogacz
Maciej Paszkowski-Rogacz
FJFlorian Jug
Florian Jug
FBFrank Buchholz
Frank Buchholz
Site-specific tyrosine-type recombinases are effective tools for genome engineering, with the first engineered variants having demonstrated therapeutic potential. So far, adaptation to new DNA target site selectivity of designer-recombinases has been achieved mostly through iterative cycles of directed molecular evolution. While effective, directed molecular evolution methods are laborious and time consuming. Here we present RecGen (Recombinase Generator), an algorithm for the intelligent generation of designer-recombinases. We gather the sequence information of over one million Cre-like recombinase sequences evolved for 89 different target sites with which we train Conditional Variational Autoencoders for recombinase generation. Experimental validation demonstrates that the algorithm can predict recombinase sequences with activity on novel target-sites, indicating that RecGen is useful to accelerate the development of future designer-recombinases.

31 January 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
LMLiliya Mukhametzyanova
Liliya Mukhametzyanova
LSLukas Theo Schmitt
Lukas Theo Schmitt
JTJulia Torres-Rivera
Julia Torres-Rivera
TRTeresa Rojo-Romanos
Teresa Rojo-Romanos
FLFelix Lansing
Felix Lansing
FBFrank Buchholz
Frank Buchholz
Recombinases have several potential advantages as genome editing tools compared to nucleases and other editing enzymes, but the process of engineering them to efficiently recombine predetermined DNA targets demands considerable investment of time and labor. Here we sought to harness zinc-finger DNA-binding domains (ZFDs) to program recombinase binding by developing fusions, in which ZFDs are inserted into recombinase coding sequences. By screening libraries of hybrid proteins, we optimized the insertion site, linker length, spacing and ZFD orientation and generated Cre-type recombinases that remain dormant unless the insertionally fused ZFD binds its target site placed in the vicinity of the recombinase binding site. The developed fusion improved targeted editing efficiencies of recombinases by four-fold and abolished measurable off-target activity in mammalian cells. The ZFD-dependent activity is transferable to a recombinase with relaxed specificity, providing the means for developing fully programmable recombinases. Our engineered recombinases provide improved genome editing tools with increased precision and efficiency.

20 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FLFelix Lansing
Felix Lansing
LMLiliya Mukhametzyanova
Liliya Mukhametzyanova
TRTeresa Rojo-Romanos
Teresa Rojo-Romanos
KIKentaro Iwasawa
Kentaro Iwasawa
MKMasaki Kimura
Masaki Kimura
FBFrank Buchholz
Frank Buchholz
Despite advances in nuclease-based genome editing technologies, correcting human disease-causing genomic inversions remains a challenge. Here, we describe the potential use of a recombinase-based system to correct the 140 kb inversion of the F8 gene frequently found in patients diagnosed with severe Hemophilia A. Employing substrate-linked directed molecular evolution, we develop a coupled heterodimeric recombinase system (RecF8) achieving 30% inversion of the target sequence in human tissue culture cells. Transient RecF8 treatment of endothelial cells, differentiated from patient-derived induced pluripotent stem cells (iPSCs) of a hemophilic donor, results in 12% correction of the inversion and restores Factor VIII mRNA expression. In this work, we present designer-recombinases as an efficient and specific means towards treatment of monogenic diseases caused by large gene inversions.

9 May 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MJMilica Jelicic
Milica Jelicic
LSLukas Theo Schmitt
Lukas Theo Schmitt
MPMaciej Paszkowski-Rogacz
Maciej Paszkowski-Rogacz
AWAngelika Walder
Angelika Walder
NSNadja Schubert
Nadja Schubert
FBFrank Buchholz
Frank Buchholz
Tyrosine-type site-specific recombinases (Y-SSRs) are versatile tools for genome engineering due to their ability to mediate excision, integration, inversion and exchange of genomic DNA with single nucleotide precision. The ever-increasing need for sophisticated genome engineering is driving efforts to identify novel SSR systems with intrinsic properties more suitable for particular applications. In this work, we develop a systematic computational workflow for annotation of putative Y-SSR systems and apply this pipeline to identify and characterize eight new naturally occurring Cre-type SSR systems. We test their activity in bacterial and mammalian cells and establish selectivity profiles for the new and already established Cre-type SSRs with regard to their ability to mutually recombine their target sites. These data form the basis for sophisticated genome engineering experiments using combinations of Y-SSRs in research fields including advanced genomics and synthetic biology. Finally, we identify putative pseudo-sites and potential off-targets for Y-SSRs in the human and mouse genome. Together with established methods for altering the DNA-binding specificity of this class of enzymes, this work should facilitate the use of Y-SSRs for future genome surgery applications.

24 December 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JHJenna Hoersten
Jenna Hoersten
GRGloria Ruiz-Gómez
Gloria Ruiz-Gómez
FLFelix Lansing
Felix Lansing
TRTeresa Rojo-Romanos
Teresa Rojo-Romanos
LSLukas Theo Schmitt
Lukas Theo Schmitt
FBFrank Buchholz
Frank Buchholz
Tyrosine site-specific recombinases (SSRs) represent a versatile genome editing tool with considerable therapeutic potential. Recent developments to engineer and evolve SSRs into heterotetramers to improve target site flexibility signified a critical step towards their broad utility in genome editing. However, SSR monomers can form combinations of different homo- and heterotetramers in cells, increasing their off-target potential. Here, we discover that two paired mutations targeting residues implicated in catalysis lead to simple obligate tyrosine SSR systems, where the presence of all distinct subunits to bind as a heterotetramer is obligatory for catalysis. Therefore, only when the paired mutations are applied as single mutations on each recombinase subunit, the engineered SSRs can efficiently recombine the intended target sequence, while the subunits carrying the point mutations expressed in isolation are inactive. We demonstrate the utility of the obligate SSR system to improve recombination specificity of a designer-recombinase for a therapeutic target in human cells. Furthermore, we show that the mutations render the naturally occurring SSRs, Cre and Vika, obligately heteromeric for catalytic proficiency, providing a straight-forward approach to improve their applied properties. These results facilitate the development of safe and effective therapeutic designer-recombinases and advance our mechanistic understanding of SSR catalysis.